Copyright
©The Author(s) 2021.
World J Virol. Mar 25, 2021; 10(2): 34-52
Published online Mar 25, 2021. doi: 10.5501/wjv.v10.i2.34
Published online Mar 25, 2021. doi: 10.5501/wjv.v10.i2.34
Table 3 Summary of ongoing clinical trials of N-acetyl cysteine and corona virus disease 2019
| Nct | Drug or other interventions | Diseases | Location (State, Country) | Status (Recruiting or completed) | Results (Yes or not available) | Phase |
| NCT04455243 | N-acetyl cysteine vs placebo | COVID 19 | Riyadh, Saudi Arabia | Not yet recruiting | Pending | 3 |
| NCT04374461 | N-acetyl cysteine vs peripheral blood | COVID 19 | New York, United States | Trial began May 2020 | Pending, expected May 2022 | 2 |
| NCT04419025 | N-acetyl cysteine | COVID 19 SARS COV 2, SARS associated Coronavirus disease, Oxidative stress | Massachusetts, United States | Trial began September 2020 | Pending, expected May 2021 | 4 |
| NCT04458298 | OP-101 (Dendrimer N-Acetylcysteine) Placebo | COVID 19 | California, United States | Trial began July 2020 | Pending, expected February 2021 | 2 |
- Citation: Dominari A, Hathaway III D, Kapasi A, Paul T, Makkar SS, Castaneda V, Gara S, Singh BM, Agadi K, Butt M, Retnakumar V, Chittajallu S, Taugir R, Sana MK, KC M, Razzack S, Moallem N, Alvarez A, Talalaev M. Bottom-up analysis of emergent properties of N-acetylcysteine as an adjuvant therapy for COVID-19. World J Virol 2021; 10(2): 34-52
- URL: https://www.wjgnet.com/2220-3249/full/v10/i2/34.htm
- DOI: https://dx.doi.org/10.5501/wjv.v10.i2.34